Beneficial effects of steroid therapy for Mikulicz's disease SIR, Mikulicz's disease (MD) represents a unique condition involving symmetrical enlargement of the lacrimal and salivary glands, the cause of which is unknown. It has been included within the diagnostic criteria for primary Sjo¨gren's syndrome (SS) due to their histological resemblance [1] . However, it is clear that the pathogenesis of MD differs from that of SS because an elevated serum IgG4 concentration and infiltration of abundant plasmacytes with IgG4 into the lacrimal and salivary glands are seen in MD patients [2] . Clinically, MD exhibits good responsiveness to glucocorticoids, showing improvements in not only lacrimal and salivary gland swelling but also secretion. We attempted to objectively document this phenomenon and to serologically evaluate steroid efficacy.
Analyses were performed in eight MD patients (two men, six women) who consulted doctors at Sapporo Medical University between April 1997 and January 2005. MD was diagnosed according to the following criteria: (i) persistent (more than 3 months) symmetrical swelling of more than two lacrimal and major salivary glands; (ii) prominent mononuclear infiltration of lacrimal and salivary glands; and (iii) exclusion of other diseases that exhibit glandular swelling, such as sarcoidosis or lymphoproliferative disease [2] . Lacrimal gland function was evaluated by Schirmer's test, and salivary gland function was examined by Saxon's test. IgG subclass was measured by nephelometry. These tests were performed before and after treatment. Mann-Whitney's U-test was used for data comparison, and values of P<0.05 were considered statistically significant. (Fig. 1) .
Glucocorticoids have long been known to effectively improve lacrimal and salivary gland swelling in MD. However, we noted that sicca symptoms were improved when we followed MD patients being treated with steroids. The present results confirmed a tendency for improvement in lacrimal and salivary secretion 2-3 months from the start of steroid treatment in MD. On the other hand, in SS, steroid therapy makes the lacrimal and salivary glands smaller, but is not able to improve gland secretion. SS is an autoimmune disease that mainly destroys glands. We initially hypothesized that steroids are not effective in SS because it is diagnosed after some degree of progression, while steroids are effective in MD because it is diagnosed earlier (onset of changes in facial appearance). However, our MD cases suffered from dryness for several years, and yet gland function improved after glucocorticoid administration. Tsubota reported fewer apoptotic cells in the lacrimal glands in MD when compared with SS [3], and we observed this phenomenon in salivary glands in MD [4] . The low number of apoptotic cells is thought to be related to the reversibility of gland secretion in MD.
The present analysis proves that different approaches to secretory function are necessary for MD and SS. In SS, cevimeline hydrochloride stimulates the remaining gland function and promotes secretion; however, active steroid treatment is of particular value in MD because glandular destruction has not occurred.
One of the serological characteristics of MD is an elevated concentration of IgG4. In addition, the ratio of serum IgG4 to total IgG is 34.85%, while in healthy controls the ratio is about 4%. It is known that the ratio does not vary with race, sex or age after adulthood. We found that the serum IgG4/total IgG ratio decreased significantly in MD patients after steroid therapy, although it is expected that steroids would decrease IgG4 concentration as a result of immune suppression. This phenomenon may be related to disease activity and the subsequent improvement in symptoms. However, in our MD cases the serum IgG4/total IgG ratio failed to normalize, and increased after tapering or interrupting the steroid dose (<5 mg prednisolone/ day). We believe that 5-7.5 mg prednisolone/day is necessary to maintain disease suppression. In contrast to the abbreviations that are generally accepted nowadays for conventional DMARDs, such as MTX, AZA and SSZ, this inhomogeneous coding for biologicals appears rather confusing and does not support an easy understanding of figures and tables addressing the outcome of biologicals-related research and clinical trials. Therefore, it would be recommendable to initiate a unifying abbreviation system that meets both the need for practicability and logic as well as applicability for all present and upcoming biologicals in rheumatology. For this purpose, the following algorithm of a three-letter-coding system is suggested for discussion. The first two letters are the first two letters of the generic, i.e. IN for infliximab, ET for etanercept, AD for adalimumab, etc. The third letter indicates the biological structure or class of the drug, i.e. X for a chimeric monoclonal antibody, Z for a humanized monoclonal antibody, M for a human monoclonal antibody, C for a soluble receptor/receptor-antibody fusion protein, and R for a receptor antagonist. Table 1 shows the resulting codes for the individual biologicals actually used in rheumatology. Sacroiliitis presenting as sciatica SIR, Sciatica is a common presentation but the underlying cause may be sacroiliitis, which differs in prognosis and treatment options. We present two cases of sacroiliitis presenting as sciatica. The first case is a 28-yr-old man who for 18 months had recurrent episodes of left buttock pain radiating down to the lower calf, typical of sciatic pain. Straight leg raising and femoral nerve stretch tests were negative and MRI of the lumbar spine showed no evidence of disc herniation. MRI of the pelvis demonstrated marked inflammation of the left sacroiliac joint. Symptoms settled gradually with ibuprofen and conservative management. He presented 15 months later with similar classical sciatica symptoms, but this time on the right side. MRI revealed rightsided sacroiliitis and the previously involved left sacroiliac joint was now normal (Fig. 1) . Diagnosis of a reactive sacroiliitis was made, and symptoms resolved with non-steroidal antiinflammatory (NSAID) therapy.
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The second case is that of a 29-yr-old sports consultant who presented with low back pain and classical sciatic pain radiating into the left ankle, and a positive straight leg raising test. X-rays revealed periarticular sclerosis of both sacroiliac joints, with possible fusion on the left side. Further history revealed low-grade psoriasis and iritis and a diagnosis of psoriatic spondyloarthritis was made. Symptoms improved with physiotherapy and valdecoxib.
Sacroiliitis causing symptoms of sciatica have been reported in a handful of cases [1, 2] . But how can sacroiliitis cause symptoms mimicking sciatica? Traditionally, sciatica was thought to be due to mechanical nerve root compression caused by intervertebral disc herniation. However, it is now evident that radicular pain is not purely mechanical, and that nerve root inflammation and subsequent nerve injury is important. In fact, up to 76% of people without symptoms of back pain or sciatica have disc herniation on MRI, and not all patients with sciatica have disc herniation on MRI [3] . Inflammatory mediators, including pro-inflammatory cytokines released from the nucleus pulposus, may contribute FIG. 1. STIR angled coronal MRI demonstrating bone oedema along the right sacroiliac joint in keeping with inflammatory change, with normalized left sacroiliac joint. 
